Search Results - "Pande, Nikhil"

Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial by Noronha, Vanita, Joshi, Amit, Patil, Vijay Maruti, Agarwal, Jaiprakash, Ghosh-Laskar, Sarbani, Budrukkar, Ashwini, Murthy, Vedang, Gupta, Tejpal, D'Cruz, Anil K, Banavali, Shripad, Pai, Prathamesh S, Chaturvedi, Pankaj, Chaukar, Devendra, Pande, Nikhil, Chandrasekharan, Arun, Talreja, Vikas, Vallathol, Dilip Harindran, Mathrudev, Vijayalakshmi, Manjrekar, Aparna, Maske, Kamesh, Bhelekar, Arati Sanjay, Nawale, Kavita, Kannan, Sadhana, Gota, Vikram, Bhattacharjee, Atanu, Kane, Shubhada, Juvekar, Shashikant L, Prabhash, Kumar

“…Purpose Chemoradiation with cisplatin 100 mg/m given once every 3 weeks is the standard of care in locally advanced head and neck squamous cell cancer…”
Get full text

ROS1 mutation non-small cell lung cancer-access to optimal treatment and outcomes by Joshi, Amit, Pande, Nikhil, Noronha, Vanita, Patil, Vijay, Kumar, Rajiv, Chougule, Anuradha, Trivedi, Vaishakhi, Janu, Amit, Mahajan, Abhishek, Prabhash, Kumar

“…ROS1 oncogenic fusion, which was first identified by Rikova et al, is reported to be present in 1%-2% of non-small cell lung cancers (NSCLCs) and is defined as…”
Get full text

Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial by Patil, Vijay M., Menon, Nandini, Chatterjee, Abhishek, Tonse, Raees, Choudhari, Amit, Mahajan, Abhishek, Puranik, Ameya D., Epari, Sridhar, Jadhav, Monica, Pathak, Shruti, Peelay, Zoya, Walavalkar, Rutuja, Muthuluri, Hemanth K., Ravi Krishna, Madala, Chandrasekharan, Arun, Pande, Nikhil, Gupta, Tejpal, Banavali, Shripad, Jalali, Rakesh

“…Recurrent glioblastoma (GBM) has dismal outcomes and limited treatment options. Mebendazole (MBZ) has activity in glioma both in-vivo and in-vitro, and is well…”
Get full text

Low prevalence of deficient mismatch repair (dMMR) protein in locally advanced rectal cancers (LARC) and treatment outcomes by Ostwal, Vikas, Pande, Nikhil S, Engineer, Reena, Saklani, Avanish, deSouza, Ashwin, Ramadwar, Mukta, Sawant, Suvarna, Mandavkar, Sarika, Shrirangwar, Sameer, Kataria, Pritam, Patil, Prachi, Shetty, Omshree, Ramaswamy, Anant

“…The available evidence in locally advanced rectal cancer (LARC) suggests a low prevalence of deficient mismatch repair (dMMR) protein status, approximating…”
Get full text

Incidence and impact of Dihydropyrimidine dehydrogenase gene mutation on neoadjuvant chemotherapy in head and neck cancers by Chougule, Anuradha, PhD, Patil, Vijay M., MBBS, MD, DM, Noronha, Vanita, MBBS, MD, DM, Joshi, Amit, MBBS, MD, DM, Turkkar, Siddharth, MBBS, MD, Chandrasekharan, Arun, MBBS, MD, Pande, Nikhil, MBBS, MD, Bagayatkar, Priyanka, BSc, Prabhash, Kumar, MBBS, MD, DM

Get full text

Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer by Noronha, Vanita, Pande, Nikhil, Joshi, Amit, Patil, Vijay, Trivedi, Vaishakhi, Chougule, Anuradha, Janu, Amit, Mahajan, Abhishek, Talreja, Vikas, Prabhash, Kumar

“…Abstract Introduction: The treatment of lung cancer is not defined in the third-line setting and remains an unanswered question. Erlotinib is the only drug…”
Get full text

Pazopanib use preceding curative surgery in low rectal gastrointestinal stromal tumors after imatinib failure: A case report by Pande, Nikhil, Shetty, Omshree, Boppana, Mounika, Ramaswamy, Anant, Saklani, Avanish, Shetty, Nitin, Ostwal, Vikas

Get full text

Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients by Patil, Vijay, Joshi, Amit, Noronha, Vanita, Bhattacharjee, Atanu, Dhumal, Sachin, Chandrakanth, M. V., Karpe, Ashay, Talreja, Vikas, Chandrasekharan, Arun, Turkar, Siddharth, Pande, Nikhil, Ramaswamy, Anant, Prabhash, Kumar

“…Abstract Background: Quality-adjusted time without toxicity (Q-TWiST) and quality of life (QOL) are indicators of benefit provided by different chemotherapy…”
Get full text

Shadow study: randomized comparison of clinic with video follow-up in glioma undergoing adjuvant temozolomide therapy by Patil, Vijay M, Pande, Nikhil, Chandrasekharan, Arun, Tonse, Raees, Krishnatry, Rahul, Goda, Jayant S, Dsouza, Hollis, Vallathol, Dilip Harindran, Chakraborty, Santam, Gupta, Tejpal, Jalali, Rakesh

“…This study was designed with a primary objective to study the rate of agreement in treatment plan and decisions between video follow-up (VF) and conventional…”
Get full text

Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of a Phase III randomized trial to compare the benefit of gefitinib versus pemetrexed/carboplatin for epidermal growth factor receptor-mutated non-small cell lung cancer by Vijay Patil, Vanita Noronha, Amit Joshi, Anuradha Chougule, Atanu Bhattacharjee, Alok Goel, Vikas Talreja, Nandini Menon, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash

“…Background:> In an open-label, Phase III randomized study, gefitinib was found to be superior to pemetrexed-platinum in terms of progression-free survival in…”
Get full text

Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation? by Joshi, Amit, Patil, Vijay, Noronha, Vanita, Chougule, Anuradha, Bhattacharjee, Atanu, Kumar, Rajiv, Goud, Supriya, More, Sucheta, Ramaswamy, Anant, Karpe, Ashay, Pande, Nikhil, Chandrasekharan, Arun, Goel, Alok, Talreja, Vikas, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar

“…This study was designed to evaluate the differential effect of epidermal growth factor receptor (EGFR) mutation status (exon 19 vs. 21) on progression-free…”
Get full text

Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed-carboplatin chemotherapy by Noronha, Vanita, Patil, Vijay, Joshi, Amit, Chougule, Anuradha, Bhattacharjee, Atanu, Kumar, Rajiv, More, Sucheta, Goud, Supriya, Karpe, Ashay, Ramaswamy, Anant, Pande, Nikhil, Chandrasekharan, Arun, Goel, Alok, Talreja, Vikas, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar

“…EGFR mutation subtype is a recognised factor impacting outcomes of patients receiving oral tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer…”
Get full text

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study by Ramaswamy, Anant, Ostwal, Vikas, Pande, Nikhil, Sharma, Atul, Patil, Shekar, Thippeswamy, Ravi, Ghadyalpatil, Nikhil, Roy, Rakesh, Peshwe, Harish, Poladia, Bhavesh, Rajamanickam, Deepan, Rangarajan, Bharat, Neelesh Reddy, P. R., Pandita, Vimal, Mukherjee, Ashis, Thoke, Aniket, Sarkar, Abhijit, Satish, C. T., Shashidara, H., Banavali, S. D.

“…Abstract Background: Regorafenib is considered a standard of care as third-line therapy in metastatic colorectal cancers (mCRCs). Materials and Methods: The…”
Get full text

Hypothyroidism post-chemoradiation on outcomes in head-and-neck cancer by Vijay M Patil, Vanita Noronha, Amit Joshi, Tanmoy Kumar Mandal, Atanu Bhattacharjee, Alok Goel, Vikas Talreja, Arun Chandrasekharan, Nikhil Pande, Anant Ramaswamy, Kumar Prabhash

“…Background: Hypothyroidism is a known side effect of head-and-neck cancer treatment and might improve outcomes. However, whether the development of…”
Get full text

Quality of life without toxicity or symptoms analysis of a randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel in recurrent head and neck cancer by Vijay Patil, Amit Joshi, Vanita Noronha, Sachin Dhumal, Arun Chandrasekharan, Nikhil Pande, Sameer Shrirangwar, Anup Toshniwal, Siddharth Turkar, Kushal Gupta, Vikas Talreja, Abhishek Mahajan, Shashikant Juvekar, Atanu Bhattacharjee, Kumar Prabhash

“…Background: This analysis was done with the aim to study the overall impact of docetaxel and cabazitaxel treatment using quality-adjusted time without symptoms…”
Get full text

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation? by Joshi, Amit, Noronha, Vanita, Patil, Vijay M., Chougule, Anuradha, Bhattacharjee, Atanu, Kumar, Rajiv, Goud, Supriya, More, Sucheta, Ramaswamy, Anant, Karpe, Ashay, Pande, Nikhil, Chandrasekharan, Arun, Goel, Alok, Talreja, Vikas, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar

“…Background. It is unknown whether the outcomes of second-line pemetrexed-carboplatin chemotherapy administered after progression on gefitinib are dependent on…”
Get full text

Real-world experience of checkpoint inhibitors across India: CRSF 2020-01 by Goyal, Gautam, Chandrasekharan, Arun, Avaronnan, Manuprasad, Talreja, Vikas, Bhosale, Bharatsinha Baburao, Kothari, Rushabh, Mondal, Tanmoy, Pande, Nikhil, Talele, Avinash, Poladia, Bhavesh Pradip, Agarwala, Vivek, Karpe, Ashay

“…e18862 Background: There are limited data available from India on the real-world use of checkpoint inhibitors. Hence we did this analysis across India to study…”
Get full text

A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer by Patil, Vijay Maruti, Noronha, Vanita, Joshi, Amit, Agarwal, Jaiprakash, Ghosh‐Laskar, Sarbani, Budrukkar, Ashwini, Murthy, Vedang, Gupta, Tejpal, Mahimkar, Manoj, Juvekar, Shashikant, Arya, Supreeta, Mahajan, Abhishek, Agarwal, Archi, Purandare, Nilendu, Rangarajan, Venkatesh, Balaji, Arun, Chaudhari, Sameer Vasant, Banavali, Shripad, Kannan, Sadhana, Bhattacharjee, Atanu, D’Cruz, Anil K., Chaturvedi, Pankaj, Pai, Prathamesh S., Chaukar, Devendra, Pantvaidya, Gouri, Nair, Deepa, Nair, Sudhir, Deshmukh, Anuja, Thiagarajan, Shivakumar, Mathrudev, Vijayalakshmi, Manjrekar, Aparna, Dhumal, Sachin, Maske, Kamesh, Bhelekar, Arti Sanjay, Nawale, Kavita, Chandrasekharan, Arun, Pande, Nikhil, Goel, Alok, Talreja, Vikas, Simha, Vijai, Srinivas, Sujay, Swami, Rohit, Vallathol, Dilip Harindran, Dsouza, Hollis, Shrirangwar, Sameer, Turkar, Siddharth, Abraham, George, Thanky, Aditi Harsh, Patel, Usha, Pandey, Manish Kumar, Prabhash, Kumar

“…Background Because the addition of nimotuzumab to chemoradiation in patients with locally advanced head and neck cancer improved outcomes in a phase 2 study,…”
Get full text

Distress Management in Patients With Head and Neck Cancer Before Start of Palliative Chemotherapy: A Practical Approach by Patil, Vijay, Noronha, Vanita, Joshi, Amit, Deodhar, Jayita, Goswami, Savita, Chakraborty, Santam, Ramaswamy, Anant, Dhumal, Sachin, M V, Chandrakanth, Karpe, Ashay, Pande, Nikhil, Talreja, Vikas, Chandrasekharan, Arun, Turkar, Siddharth, Prabhash, Kumar

“…This study reports the incidence of distress, the factors associated with distress, and a practical strategy to resolve distress in patients with head and neck…”
Get full text

Effect of Mindfulness-Based Art Therapy (MBAT) on Psychological Distress and Spiritual Wellbeing in Breast Cancer Patients Undergoing Chemotherapy by Joshi, Anjali Mangesh, Mehta, Suchitra Ajay, Pande, Nikhil, Mehta, Ajay Omprakash, Randhe, Kamaljeet Sanjay

“…Psychological distress and spiritual well-being (SWB) are directly related to the quality of life in cancer patients. Mindfulness-Based Art Therapy (MBAT)…”
Get full text